burixafor
Small moleculeexperimental
Clinical trial activity
4 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2008 (NCT00822341)
Timeline
Indications
Mechanism of action
- C-X-C chemokine receptor type 4ANTAGONIST
CXCR4 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Nc1cc(N2CCN(CCP(=O)(O)O)CC2)nc(NCC2CCC(CNCCCNC3CCCCC3)CC2)n1- Mol. weight
- 566.73 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545224 ↗
Also known as
- burixafor
- burixafor
- burixafor
- burixafor
- tg-0054
- tg-0054
- tg-0054
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02104427 | Phase 2 | Feb 1, 2015 | Stony Brook University, TaiGen Biotechnology Co., Ltd. |
| NCT01458288 | Phase 2 | Oct 1, 2012 | Stony Brook University, TaiGen Biotechnology Co., Ltd. |
| NCT01018979 | Phase 2 | Feb 1, 2010 | Chang Gung University, Kaohsiung Medical University, National Taiwan University, TaiGen Biotechnology Co., Ltd., Taipei Veteran General hospital, Tzu Chi University |
| NCT00822341 | Phase 1 | Apr 1, 2008 | Parexel, TaiGen Biotechnology Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| TaiGen Biotechnology Co., Ltd. | For profit | 4 | 4 | 2 | 2008 |
| Stony Brook University | Academic/Hospital | 2 | 0 | 1 | 2012 |
| Chang Gung University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Kaohsiung Medical University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| National Taiwan University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Parexel | For profit | 1 | 0 | 1 | 2008 |
| Taipei Veteran General hospital | Government | 1 | 0 | 1 | 2010 |
| Tzu Chi University | Academic/Hospital | 1 | 0 | 1 | 2010 |
8 organizations
Page 1 / 1